Applicant Eligibility for Medical Device Registration under Article 11
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Article 11 of Law No. 12/2025 divides applicants into 2 categories:
- Applicants that manufacture by themselves or through commissioning (paragraph 1): they must simultaneously satisfy 4 requirements — a natural person domiciled in Macao, China or a legal person duly established in Macao, China; not being within a period of supplementary penalty, supplementary punishment or security measure prohibiting engagement in medical device business activities; not being within a period prohibiting application for registration or notification; and having no debt currently subject to compulsory enforcement through tax enforcement proceedings.
- Applicants importing devices already registered or granted marketing authorisation outside Macao (paragraph 2): for Class I and Class IIa devices, a foreign trade operator meeting the requirement on clean status described above; for Class IIb and Class III devices, a medical device trading licence holder engaged in import, export and wholesale activities (or an establishment holding a licence for the import, export and wholesale of pharmaceutical products, or a licence for the import, export and wholesale of Chinese medicine).
Applicant eligibility cannot be remedied after the fact — this is the least recoverable point of failure in the entire process.
2. Legal basis
Applicant eligibility for both manufacturing and import scenarios is governed by the following instruments, verified as of 29 October 2026.
| Regulation | Reference | Publication | Provisions |
| Medical Device Supervision System | Law No. 12/2025 (Issue No. 30/2025 of the Official Gazette) | Published on 28 July 2025; in force on 1 July 2026 | Article 11(1) (applicants manufacturing by themselves or through commissioning); Article 11(2) (applicants in import scenarios); Article 11(3) (application to managers and members of the administrative body where the applicant is a legal person) |
| Implementing Rules of the Medical Device Supervision System | Administrative Regulation No. 11/2026 (Issue No. 20/2026 of the Official Gazette) | Published on 18 May 2026; in force on 1 July 2026 | Article 10(2), items (2), (3) and (4); Article 13(1) (the formal review includes standing) |
| Regime governing the import, export and wholesale of pharmaceutical products | Decree-Law No. 58/90/M | Current version, verified as of 2026-10-29 | Provisions relating to establishments for the import, export and wholesale of pharmaceutical products |
| Regime governing the import, export and wholesale of Chinese medicine | Law No. 11/2021 | Current version, verified as of 2026-10-29 | Provisions relating to licences for the import, export and wholesale of Chinese medicine |
| Pharmaceutical Administration Bureau service information for first-time applications | Published on the government portal | Current version, verified as of 2026-10-29 | Eligibility requirements and documents to be submitted |
3. Expert insights
Insight 1: an overseas manufacturer can act as its own applicant, but it must first have a Macao entity. Article 11(1) allows natural or legal persons that manufacture by themselves or through commissioning, inside or outside the Macao Special Administrative Region of China to apply, provided that the legal person is duly established in Macao, China. In other words, once an overseas parent company establishes a subsidiary in Macao, that subsidiary holds applicant eligibility, and there is no need to route the application through a third party.
Insight 2: under the import pathway, entity requirements are tiered by risk class. Class IIb and Class III devices must be applied for by a trading licence holder, which is a higher threshold; Class I and Class IIa devices may be notified by a foreign trade operator alone. This explains why market access in Macao is markedly faster for low-risk products — the entity threshold itself is lower.
Insight 3: 2 of the 4 requirements are clean-status requirements. The requirements of not being within any prohibition period and having no debt in tax enforcement proceedings require the submission of a criminal record certificate and a certificate of no debt issued by the Finance Services Bureau. Where an overseas parent company appoints its Macao subsidiary to apply, the managers and members of the administrative body of that subsidiary must likewise submit criminal record certificates (Article 11(3)).
Insight 4: holding a licence exempts part of the documentation. Article 10(3) of the Implementing Rules provides that an applicant holding a manufacturing licence or a trading licence need not submit the documents under items (1) to (3) of paragraph 2 (applicant information, criminal record certificate and certificate of no debt). Obtaining the licence first and then applying for registration can save an entire set of administrative documents.
4. Practical recommendations
- Fix the entity before fixing the pathway: complete the establishment of the Macao entity or the application for the trading licence before starting dossier preparation.
- Prioritise licence-holder status: it exempts 3 categories of administrative documents from the registration application and reduces the risk of deficiency corrections.
- Obtain the criminal record certificate early: the purpose stated on the application must be specified as an application relating to medical device registration or notification, and the Identity Services Bureau can send it directly to ISAF.
- Obtain the certificate of no tax debt in parallel: it is issued by the Finance Services Bureau and is one of the non-remediable eligibility requirements.
5. Verification checklist
- □ It has been confirmed whether the case falls under Article 11(1) (self-manufacture) or Article 11(2) (import)
- □ The Macao entity (legal-person establishment or natural-person domicile) has been secured
- □ Criminal record certificates have been obtained (including for managers and members of the administrative body)
- □ The certificate of no debt from the Finance Services Bureau has been obtained
- □ For imported Class IIb and Class III devices, trading licence holder status has been confirmed
- □ The option of obtaining a licence first in order to exempt part of the registration documents has been assessed
Regulatory information verified as of 29 October 2026. The regulations, guidelines and effective dates described in this article are limited to the content published by the official sources listed under Legal basis as of that date; where official documents are subsequently updated, the latest published version prevails.
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Macao, China. Our team manages Health Bureau (SSM) pre-market registration and notification applications, prepares reference-approval dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us